Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer. — Stella
Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.
Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(28 sites)
Italy
Centro Di Riferimento Oncologico Di Aviano, Aviano, Italy
University Hospital Consorziale Policlinico, Bari, Italy
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia, Brescia, Italy
ASST Ospedale Maggiore di Crema, Crema, Italy
Azienda Socio Sanitaria Territoriale Di Cremona, Cremona, Italy
Careggi University Hospital, Florence, Italy
IRCCS Ospedale Policlinico San Martino, Genoa, Italy
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l., Meldola, Italy
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Istituto Europeo Di Oncologia S.r.l., Milan, Italy
ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy